一项关于HMPL-A251在晚期或转移性HER2表达实体瘤受试者中进行的Ⅰ/Ⅱa期研究
一项评估HMPL-A251在晚期或转移性HER2表达实体瘤受试者中的安全性、耐受性、药代动力学、免疫原性及初步疗效的I/IIa期研究
This is a first-in-human (FIH), phase Ⅰ/Ⅱa, open-label, multicenter clinical study of HMPL-A251 monotherapy in adult participants with unresectable, advanced or metastatic HER2-expressing solid tumors.
研究概览
详细说明
- To evaluate the safety and tolerability and to determine the maximum tolerated dose (MTD) and/or recommended dose(s) for expansion (RDE) of HMPL-A251 in participants with previously treated HER2+ solid tumors
- To characterize the safety and preliminary efficacy of HMPL-A251 at RDEs to determine recommended dose(s) for phase 2 (RP2D) or phase 3 (RP3D) in participants with selected HER2-expressing solid tumors
研究类型
注册 (估计的)
阶段
- 阶段2
- 阶段1
联系人和位置
学习地点
-
-
-
Beijing、中国
- 招聘中
- Peking University First Hospital
-
接触:
- Shikai Wu
- 电话号码:+86 18910715326
- 邮箱:skywu4329@sina.com
-
接触:
- Yu Fan
-
Changsha、中国
- 招聘中
- Hunan Cancer Hospital
-
接触:
- Quchang Oyang
- 电话号码:0731-89762161
- 邮箱:Oyqc1969@126.com
-
Guangzhou、中国
- 招聘中
- Sun Yat-sen University Cancer Center
-
接触:
- Shusen Wang
- 电话号码:020-87342693
- 邮箱:Wangshus@susucc.org.cn
-
Hefei、中国
- 招聘中
- The First Affiliated Hospital of Anhui Medical University
-
接触:
- Yingying Du
- 电话号码:0551-65908511
- 邮箱:duyy1980@126.com
-
Shanghai、中国
- 招聘中
- Fudan University Shanghai Cancer Center
-
接触:
- Jian Zhang
-
接触:
- Xiaohua Wu
- 电话号码:18121299168
- 邮箱:wu.xh@fudan.edu.cn
-
Shenyang、中国
- 招聘中
- The First Hospital of China Medical University
-
接触:
- Funan Liu
- 电话号码:13609877906
- 邮箱:lfn_clinical@126.com
-
Zhengzhou、中国
- 招聘中
- Henan Cancer Hospital
-
接触:
- Min Yan
- 电话号码:+86 157 1385 7388
- 邮箱:ym200678@163.com
-
-
-
-
Colorado
-
Denver、Colorado、美国、80218
- 招聘中
- SCRI HealthONE
-
接触:
- Gerald Falchook
- 电话号码:940-365-6217
- 邮箱:bianca.reyes@scri.com
-
-
Florida
-
Plantation、Florida、美国、33322
- 招聘中
- BRCR Global
-
接触:
- Harshad Amin
- 电话号码:561-447-0614
- 邮箱:alejandrop@brcrglobal.com
-
Plantation、Florida、美国、33322
- 招聘中
- Florida Clinical Trials Group LLC (Plantation)
-
接触:
- Harshad Amin
- 电话号码:772-297-3057
- 邮箱:clinops@floridactg.com
-
Tamarac、Florida、美国、33321
- 尚未招聘
- Florida Clinical Trials Group LLC (Tamarac)
-
接触:
- Chintan Ghandi
-
-
New Jersey
-
East Brunswick、New Jersey、美国、08816
- 尚未招聘
- START New Jersey
-
接触:
- Bruno Fang
-
-
New York
-
New York、New York、美国、10065
- 尚未招聘
- Memorial Sloan Kettering Cancer Center
-
接触:
- Vicky Makker
-
-
Ohio
-
Cleveland、Ohio、美国、44195
- 招聘中
- Cleveland Clinic Taussig Cancer Center
-
接触:
- WenWee Ma
- 电话号码:216-559-9815
- 邮箱:keaneyh@ccf.org
-
-
Washington
-
Tacoma、Washington、美国、98405
- 尚未招聘
- Northwest Medical Specialties, PLLC
-
接触:
- Jorge Chaves
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Histologically confirmed unresectable advanced or metastatic disease.
- Have at least one measurable lesion per RECIST v1.1;
- Life expectancy ≥ 12 weeks;
- Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0-1;
- Weight ≥ 35 kg;
Exclusion Criteria:
- An established diagnosis of type I diabetes mellitus or uncontrolled type II diabetes mellitus.
- Use of strong inhibitors or strong inducers of cytochrome P450 3A4 enzyme (CYP3A4), and inhibitors of P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP) within 5 elimination half-lives or 2 weeks (whichever is longer) before the first dose of study drug;
- Toxicity from prior anti-tumor therapy has not recovered to Grade 1 or baseline prior to the first dose of study drug (except alopecia). Participants with chronic Grade 2 toxicities may be eligible after discussion between the investigator and Sponsor Medical Monitor (e.g., Grade 2 chemotherapy-induced neuropathy);
- Baseline blood amylase or lipase exceeds the normal range and are judged by the investigators to be clinically significant;
- Spinal cord compression, leptomeningeal disease, or clinically active central nervous system (CNS) metastases, defined as untreated or symptomatic, or requiring therapy with corticosteroids or anticonvulsants to control associated symptoms;
- Major surgery within 28 days prior to the first dose of study drug. Participants must have recovered adequately from the toxicity and/or complications from the intervention prior to the first dose of study drug(s);
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:顺序分配
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Part A(Phase I)
Dose Escalation |
Six dose cohorts are planned for the Dose Escalation phase; at least three participants with solid tumors will be enrolled in each dose cohort. Bayesian optimal interval design with backfill (BF-BOIN, Zhao, 2023) will be used to guide dose escalation and determine the MTD and/or RDE of HMPL-A251. All study participants will receive HMPL-A251 as IV infusion until PD, intolerable toxicity, or other protocol-specified criteria for ending study treatment, whichever occurs first. Participants will be randomized in a 1:1 ratio to receive treatment in two RDEs levels (approximately 15 participants per dose level) for each cohort. All study participants will receive HMPL-A251 as IV infusion until PD, intolerable toxicity, or other protocol-specified criteria for ending study treatment, whichever occurs first. |
|
实验性的:Part B(Phase IIa)
Dose Expansion/Dose Optimization |
Six dose cohorts are planned for the Dose Escalation phase; at least three participants with solid tumors will be enrolled in each dose cohort. Bayesian optimal interval design with backfill (BF-BOIN, Zhao, 2023) will be used to guide dose escalation and determine the MTD and/or RDE of HMPL-A251. All study participants will receive HMPL-A251 as IV infusion until PD, intolerable toxicity, or other protocol-specified criteria for ending study treatment, whichever occurs first. Participants will be randomized in a 1:1 ratio to receive treatment in two RDEs levels (approximately 15 participants per dose level) for each cohort. All study participants will receive HMPL-A251 as IV infusion until PD, intolerable toxicity, or other protocol-specified criteria for ending study treatment, whichever occurs first. |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Maximum Tolerated Dose (MTD)
大体时间:Approximately 12 months
|
At least three participants will be enrolled in each dose cohort. Bayesian optimal interval design with backfill (BF-BOIN) will be used to guide dose escalation and to determine the MTD of HMPL-A251 |
Approximately 12 months
|
|
Recommended doses for expansion (RDE)
大体时间:Approximately 12 months
|
The RDE will be selected by evaluating all available data from the following criteria under consideration: Determination of MTD achieved during the dose escalation part; Safety data obtained across all different doses tested; Tolerability data, such as chronic toxicities, discontinuations, or withdrawals for toxicity that occur beyond the DLT period; PK data collected at the time of evaluation; Preliminary efficacy data. |
Approximately 12 months
|
|
Overview of Treatment-emergent Adverse Events (TEAEs)
大体时间:Approximately 24 months
|
All TEAEs will be graded according to NCI CTCAE v6.0 and coded using the Medical Dictionary for Regulatory Activities (MedDRA). |
Approximately 24 months
|
|
Objective Response Rate (ORR)
大体时间:At least 6 weeks post dose of first participant up to approximately 24 months
|
ORR is defined as the proportion of participants with Best objective response (BOR) of confirmed complete response (CR) or partial response (PR), as per investigator's assessment according to RECIST v1.1. |
At least 6 weeks post dose of first participant up to approximately 24 months
|
|
Recommended doses for phase II or III studies (RP2D or RP3D) of HMPL-A251
大体时间:Approximately 12 months
|
The RP2D or RP3D will be selected by evaluating all available data from the following criteria under consideration: Determination of MTD achieved during the dose escalation part; Safety data obtained across all different doses tested; Tolerability data; PK data; efficacy data. |
Approximately 12 months
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Disease control rate (DCR)
大体时间:Approximately 2 years
|
The proportion of participants with BOR of confirmed CR, confirmed PR, or stable disease (SD) lasting at least 5 weeks. |
Approximately 2 years
|
|
Duration of response (DoR)
大体时间:Approximately 2 years
|
Only applies to participants whose BOR is confirmed CR or PR and is defined as the time from the first occurrence of objective tumor response (CR or PR) to the date of first radiographic PD or death due to any cause. |
Approximately 2 years
|
|
Time to response (TTR)
大体时间:Approximately 2 years
|
Only applies to participants whose BOR is confirmed CR or PR and is defined as the time from the first dose of study dose to the first occurrence of objective tumor response (CR or PR) |
Approximately 2 years
|
|
Progression-free survival (PFS)
大体时间:Approximately 2 years
|
The time from the first dose of study drug to the date of first radiographic PD per RECIST v1.1 or death due to any cause, whichever occurs first. |
Approximately 2 years
|
|
Overall survival (OS)
大体时间:Approximately 2 years
|
Every 12 weeks (± 7 days) until death, withdrawal of consent for follow-up, lost to follow-up or end of study, whichever occurs first. |
Approximately 2 years
|
|
Maximum plasma/serum concentration (Cmax)
大体时间:Cycle 1 and Cycle 3 (21-day cycle)
|
Observed maximum plasma/serum concentration of HMPL-A251, total anti-HER2 antibody, and HM5041609; only applies to Cycles 1 and 3. |
Cycle 1 and Cycle 3 (21-day cycle)
|
|
Time to maximum plasma/serum concentration (Tmax)
大体时间:Cycle 1 and Cycle 3 (21-day cycle)
|
Time to observed Cmax for HMPL-A251, total anti-HER2 antibody, and HM5041609 |
Cycle 1 and Cycle 3 (21-day cycle)
|
|
Area under the plasma/serum concentration-time curve (AUC)
大体时间:Cycle 1 and Cycle 3 (21-day cycle)
|
Derived from the observed plasma/serum concentration-time data for HMPL-A251, total anti-HER2 antibody, and HM5041609 using noncompartmental analysis |
Cycle 1 and Cycle 3 (21-day cycle)
|
|
Pre-dose plasma/serum concentration (Cmin)
大体时间:Each cycle (21-day cycle); from C9, every 4 cycles, through approximately 12 months
|
Observed pre-dose plasma/serum concentration of HMPL-A251, total anti-HER2 antibody, and HM5041609. |
Each cycle (21-day cycle); from C9, every 4 cycles, through approximately 12 months
|
|
Immunogenicity of HMPL-A251
大体时间:Each cycle (21-day cycle), From C9, every 4 cycles, Approximately 12 months
|
Incidence of anti-drug antibody and neutralizing antibody against HMPL-A251 |
Each cycle (21-day cycle), From C9, every 4 cycles, Approximately 12 months
|
合作者和调查者
赞助
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他研究编号
- 2025-251-GLOB1
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.